154 related articles for article (PubMed ID: 31756326)
21. An oral GLP-1 and GIP dual receptor agonist improves metabolic disorders in high fat-fed mice.
Ma T; Lu W; Wang Y; Qian P; Tian H; Gao X; Yao W
Eur J Pharmacol; 2022 Jan; 914():174635. PubMed ID: 34800466
[TBL] [Abstract][Full Text] [Related]
22. The combination of GIP plus xenin-25 indirectly increases pancreatic polypeptide release in humans with and without type 2 diabetes mellitus.
Chowdhury S; Wang S; Patterson BW; Reeds DN; Wice BM
Regul Pept; 2013 Nov; 187():42-50. PubMed ID: 24183983
[TBL] [Abstract][Full Text] [Related]
23. Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice.
Parker JC; Irwin N; Lavery KS; Green BD; O'Harte FP; Gault VA; Flatt PR
Biol Chem; 2007 Feb; 388(2):221-6. PubMed ID: 17261085
[TBL] [Abstract][Full Text] [Related]
24. Xenin-25 potentiates glucose-dependent insulinotropic polypeptide action via a novel cholinergic relay mechanism.
Wice BM; Wang S; Crimmins DL; Diggs-Andrews KA; Althage MC; Ford EL; Tran H; Ohlendorf M; Griest TA; Wang Q; Fisher SJ; Ladenson JH; Polonsky KS
J Biol Chem; 2010 Jun; 285(26):19842-53. PubMed ID: 20421298
[TBL] [Abstract][Full Text] [Related]
25. A Novel CCK-8/GLP-1 Hybrid Peptide Exhibiting Prominent Insulinotropic, Glucose-Lowering, and Satiety Actions With Significant Therapeutic Potential in High-Fat-Fed Mice.
Irwin N; Pathak V; Flatt PR
Diabetes; 2015 Aug; 64(8):2996-3009. PubMed ID: 25883113
[TBL] [Abstract][Full Text] [Related]
26. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
Maida A; Hansotia T; Longuet C; Seino Y; Drucker DJ
Gastroenterology; 2009 Dec; 137(6):2146-57. PubMed ID: 19766644
[TBL] [Abstract][Full Text] [Related]
27. Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice.
McShane LM; Irwin N; O'Flynn D; Franklin ZJ; Hewage CM; O'Harte FP
J Endocrinol; 2016 Jun; 229(3):319-30. PubMed ID: 27098830
[TBL] [Abstract][Full Text] [Related]
28. Degradation, insulin secretion, glucose-lowering and GIP additive actions of a palmitate-derivatised analogue of xenin-25.
Martin CM; Gault VA; McClean S; Flatt PR; Irwin N
Biochem Pharmacol; 2012 Aug; 84(3):312-9. PubMed ID: 22561048
[TBL] [Abstract][Full Text] [Related]
29. Sequential induction of beta cell rest and stimulation using stable GIP inhibitor and GLP-1 mimetic peptides improves metabolic control in C57BL/KsJ db/db mice.
Pathak V; Vasu S; Gault VA; Flatt PR; Irwin N
Diabetologia; 2015 Sep; 58(9):2144-53. PubMed ID: 26048235
[TBL] [Abstract][Full Text] [Related]
30. Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice.
Pathak V; Gault VA; Flatt PR; Irwin N
Mol Cell Endocrinol; 2015 Feb; 401():120-9. PubMed ID: 25449420
[TBL] [Abstract][Full Text] [Related]
31. Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets.
Gault VA; McClean PL; Cassidy RS; Irwin N; Flatt PR
Diabetologia; 2007 Aug; 50(8):1752-62. PubMed ID: 17558485
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the degradation and metabolic effects of the gut peptide xenin on insulin secretion, glycaemic control and satiety.
Taylor AI; Irwin N; McKillop AM; Patterson S; Flatt PR; Gault VA
J Endocrinol; 2010 Oct; 207(1):87-93. PubMed ID: 20631047
[TBL] [Abstract][Full Text] [Related]
33. Metabolic effects of combined glucagon receptor antagonism and glucagon-like peptide-1 receptor agonism in high fat fed mice.
Franklin ZJ; Lafferty RA; Flatt PR; McShane LM; O'Harte FPM; Irwin N
Biochimie; 2022 Aug; 199():60-67. PubMed ID: 35439540
[TBL] [Abstract][Full Text] [Related]
34. Positive effects of GLP-1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJ db/db mice with degenerative diabetes.
Moffett RC; Patterson S; Irwin N; Flatt PR
Diabetes Metab Res Rev; 2015 Mar; 31(3):248-55. PubMed ID: 25256010
[TBL] [Abstract][Full Text] [Related]
35. Individual and combined effects of GIP and xenin on differentiation, glucose uptake and lipolysis in 3T3-L1 adipocytes.
English A; Craig SL; Flatt PR; Irwin N
Biol Chem; 2020 Oct; 401(11):1293-1303. PubMed ID: 32769216
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amide.
Irwin N; McClean PL; Cassidy RS; O'harte FP; Green BD; Gault VA; Harriott P; Flatt PR
Diabetes Metab Res Rev; 2007 Oct; 23(7):572-9. PubMed ID: 17315241
[TBL] [Abstract][Full Text] [Related]
37. Xenin-25 delays gastric emptying and reduces postprandial glucose levels in humans with and without type 2 diabetes.
Chowdhury S; Reeds DN; Crimmins DL; Patterson BW; Laciny E; Wang S; Tran HD; Griest TA; Rometo DA; Dunai J; Wallendorf MJ; Ladenson JH; Polonsky KS; Wice BM
Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(4):G301-9. PubMed ID: 24356886
[TBL] [Abstract][Full Text] [Related]
38. Characterisation of the biological activity of xenin-25 degradation fragment peptides.
Martin CM; Parthsarathy V; Pathak V; Gault VA; Flatt PR; Irwin N
J Endocrinol; 2014 May; 221(2):193-200. PubMed ID: 24520141
[TBL] [Abstract][Full Text] [Related]
39. Sustained metabolic benefits of ΔTRTX-Ac1, a tarantula venom-derived peptide, when administered together with exenatide in high-fat fed mice.
Coulter-Parkhill A; Tanday N; Cobice D; McLaughlin CM; McClean S; Gault VA; Irwin N
Diabetes Obes Metab; 2024 Jan; 26(1):329-338. PubMed ID: 37818589
[TBL] [Abstract][Full Text] [Related]
40. Metabolic effects of sustained activation of the GLP-1 receptor alone and in combination with background GIP receptor antagonism in high fat-fed mice.
Irwin N; McClean PL; Hunter K; Flatt PR
Diabetes Obes Metab; 2009 Jun; 11(6):603-10. PubMed ID: 19515180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]